High-rolling investors have positioned themselves bullish on Viking Therapeutics ( VKTX ) , and it's important for retail traders to take note.
This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in VKTX often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 8 options trades for Viking Therapeutics ( VKTX ). This is not a typical pattern.
The sentiment among these major traders is split, with 87% bullish and 0% bearish. Among all the options we identified, there was one put, amounting to $56,000, and 7 calls, totaling $414,979.
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $15.0 to $70.0 for Viking Therapeutics ( VKTX ) during the past quarter.
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Viking Therapeutics's ( VKTX ) options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Viking Therapeutics's ( VKTX ) whale trades within a strike price range from $15.0 to $70.0 in the last 30 days.
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VKTX | CALL | TRADE | BULLISH | 2.0K | 596 | ||||||
| VKTX | CALL | TRADE | BULLISH | 714 | 1 | ||||||
| VKTX | PUT | TRADE | BULLISH | 53 | 6 | ||||||
| VKTX | CALL | SWEEP | BULLISH | 351 | 2 | ||||||
| VKTX | CALL | SWEEP | BULLISH | 2.0K | 1.5K |
Viking Therapeutics Inc ( VKTX ) is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Following our analysis of the options activities associated with Viking Therapeutics ( VKTX ), we pivot to a closer look at the company's own performance.
Trading volume stands at 1,066,972, with VKTX's price up by 0.17%, positioned at $52.21.
RSI indicators show the stock to be may be oversold.
Earnings announcement expected in 29 days.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Viking Therapeutics ( VKTX ) with Benzinga Pro for real-time alerts.